Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases and anticipates milestones for the year ahead.
Copyright 2024 – Finance News Network
05 Jul 2021 - icetana Limited (ASX:ICE) CEO & Managing Director Matt Macfarlane talks about the company's AI software, which dramatically improves active security monitoring by learning normal movement patterns and highlighting abnormal movement in real time.
27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE Phase II clinical study to commence 2H20 and value drivers as the company moves toward registration.
25 Sep 2023 - Wally Graham of Resources Roadhouse at the New World Metals Conference, speaking with Cristian Moreno, Managing Director of Torque Metals (ASX:TOR).
13 Sep 2019 - Healthia Limited (ASX:HLA) Group CEO & Managing Director, Wesley Coote and Chairman, Dr Glen Richards talk about the company's FY19 results and its model of acquiring podiatry and physiotherapy clinics.
26 Feb 2020 - Renergen Limited (ASX:RLT) Managing Director and CEO, Stefano Marani provides an update on recent drilling results at the company's Virginia Gas Project in South Africa, what’s planned for this year and the potential to bring forward a second production well.
21 Feb 2023 - BluGlass Limited (ASX:BLG) President Jim Haden provides an update on the company, discussing the launch of the company's first suite of laser products, integration of the recently acquired fab facility and outlook for 2023.
16 Aug 2023 - Dr John Melki - CEO and Director - Genetic Signatures (ASX:GSS) is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.
22 Sep 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses Evergrande, the Chinese economy, implications for the Australian equity market and monetary policy.